Literature DB >> 23169499

Improvement in progression-free survival in OCEANS bevacizumab arm: a critical point of view.

Federica Tomao, Silverio Tomao, Pierluigi Benedetti Panici.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23169499     DOI: 10.1200/JCO.2012.44.6237

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Current status of bevacizumab in advanced ovarian cancer.

Authors:  Federica Tomao; Anselmo Papa; Luigi Rossi; Davide Caruso; Pierluigi Benedetti Panici; Martina Venezia; Silverio Tomao
Journal:  Onco Targets Ther       Date:  2013-07-22       Impact factor: 4.147

Review 2.  Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach.

Authors:  Federica Tomao; Anselmo Papa; Luigi Rossi; Martina Strudel; Patrizia Vici; Giuseppe Lo Russo; Silverio Tomao
Journal:  J Exp Clin Cancer Res       Date:  2013-08-01

3.  Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer: a critical consideration.

Authors:  Sara Giovannoni; Patrizia Trenta
Journal:  J Gynecol Oncol       Date:  2014-10       Impact factor: 4.401

Review 4.  Bevacizumab in ovarian cancer: A critical review of phase III studies.

Authors:  Luigi Rossi; Monica Verrico; Eleonora Zaccarelli; Anselmo Papa; Maria Colonna; Martina Strudel; Patrizia Vici; Vincenzo Bianco; Federica Tomao
Journal:  Oncotarget       Date:  2017-02-14

Review 5.  Investigating molecular profiles of ovarian cancer: an update on cancer stem cells.

Authors:  Federica Tomao; Anselmo Papa; Martina Strudel; Luigi Rossi; Giuseppe Lo Russo; Pierluigi Benedetti Panici; Francesca Romana Ciabatta; Silverio Tomao
Journal:  J Cancer       Date:  2014-03-16       Impact factor: 4.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.